This site is intended for health professionals only

Teva set for £3.2bn Ratiopharm deal

teaser

Pharmaceutical company Teva has acquired generic drug maker Ratiopharm for £3.2 billion, beating rivals Pfizer and Actavis to the deal.

The buyout, the second significant acquisition by the Israel-based firm in the past two years, was paid for by a combination of upfront cash and credit.

Ratiopharm owners, the Merckle family, put the organisation up for sale to clear debts incurred by Adolf Merckle, who took his own life in January 2009.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Ludwig Merckle said: “The separation of Ratiopharm is a painful step for us as the founding family (but) I believe that joining forces with the world’s largest generic company will enable Ratiopharm to continue its path of growth and success.”

The move is expected to receive regulatory approval by the end of the year. It comes eight months after Teva bought Barr Pharmaceuticals for £4.9 billion.

Copyright Press Association 2010
Teva
Ratiopharm






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x